CytomX Therapeutics (CTMX) Tops Q2 EPS by 17c

CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.02), $0.17 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $13.68 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• RH (RH) Tops Q1 EPS by 12c
• Morgan Stanley Upgrades Towa Pharmaceutical Co Ltd (4553:JP) to Overweight